Q2 2026 Q linea AB Earnings Call Transcript
Key Points
- Q-linea AB (OSTO:QLINEA) shipped five ASTar instruments during the quarter, indicating progress in market penetration.
- The company received FDA approval for an expanded menu, enhancing its competitive position in the US market.
- Global expansion is underway with four new distribution agreements in new markets, signaling growth potential.
- Year-on-year operating income improved significantly due to cost reduction programs and restructuring efforts.
- The company is recognized as a leader in rapid antimicrobial susceptibility testing, with strong clinical performance and a superior menu offering.
- No capital sales of instruments were recognized during the quarter, impacting revenue generation.
- Consumable revenue remained roughly at the same level as in Q1, indicating a need for increased utilization.
- Operating results were still negative, although improved, reflecting ongoing financial challenges.
- Cash flow from operating activities was negative, with a SEK5 million prepayment impacting cash flow.
- The company reduced its workforce significantly, which could impact operational capacity and morale.
Welcome to the Q-linea Q2 report 2026. (Operator Instructions) Now I will hand the conference over to CEO, Stuart Gander; and CFO, Annika Blondeau Henriksson. Please go ahead.
Hello, and thank you, everyone, for joining during the summer here for Q-linea's second-quarter report. You have Stuart Gander, the CEO and President, speaking, and I'm joined by our new CFO, Annika Blondeau Henriksson, who will come on later to speak to our financials.
The usual disclaimer here, which we'll take as read and understood going forward. And our agenda tracks to our previous quarterly readouts here. I'll spend a little bit of time talking to the commercial update in the market and how we see things unfolding with a focus on the US market.
Then we'll speak to the outlook through the year, some of the big things happening and what our operational priorities are before I turn it over to Annika to talk to our financial performance through the quarter and obviously come back around to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
